English   Castellano   Català

Our business model is based on re-profiling of known drugs for their development and commercial use in central nervous system (CNS) diseases from its Preclinical Phase up to Clinical Phase II with the aim to increase their value and transfer them to third parties by either commercialization or out licensing.

Significant advantages of compound repositioning is a reduced research time and a lower technological risk of drug development, since the repositioned molecule has already passed preclinical toxicological tests, its safety is known and the risks of failure for adverse events are reduced. This is reflected in a lower total cost of the projects, a reduced need for investment and time needed to bring a drug to market.